Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2330

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 2330
---
 expense 
     400,825  
     37,356  
     460,722 
  
    Stock-based compensation 
     924,668  
     4,431  
     96,896 
  
    Amortization of right-to-use operating lease asset 
     609,339  
     115,859  
     656,476 
  
    Amortization of debt discount 
     -  
     (1,875) 
     - 
  
    Non-cash interest expense 
     -  
     -  
     35,655 
  
    Gain on revaluation of earnout and derivative liabilities 
     (4,880,000) 
     (320,117) 
     (290,264)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (87,088) 
     142,687  
     (112,321)
  
    Accounts payable 
     130,032  
     128,429  
     1,280,560 
  
    Accrued liabilities 
     2,342,593  
     (50,370) 
     44,239 
  
    Operating lease liability 
     (647,503) 
     (121,589) 
     (672,373)
  
    Net cash used in operating activities 
     (12,278,569) 
     (637,400) 
     (5,789,987)

    Cash flows from financing activities: 

    Proceeds from issuance of convertible notes 
     -  
     -  
     605,230 
  
    Issuance costs for convertible notes 
     -  
     -  
     (41,193)
  
    Common stock subscription deposit 
     -  
     -  
     1,875 
  
    Cash proceeds from exercise of common stock options 
     -  
     -  
     5,766 
  
    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     6,757,700  
     -  
     - 
  
    Advances from shareholder 
     13,731  
     -  
     - 
  
    Payment of sponsor loans 
     (19,